Galectin Therapeutics GALT 深 滬
等待開盤 07-18 09:30:00 美东时间
2.89
+0.040
+1.40%
華盛通- 最 高2.89
- 今 開2.85
- 成交量 26.50万股
- 最 低 2.78
- 昨 收 2.85
- 總市值 1.83亿
- 52周最高 3.9035
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.726
- 委 比 91.86%
- 總股本 6329.16万
- 歷史最高 19.11
- 量 比 0.67
- 振 幅 3.86%
- 歷史最低 0.49
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galectin Therapeutics Secures $10M Credit Line for Growth
The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On July ...
07-09 20:16
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
<p>Galectin Therapeutics Inc. has secured a $10 million unsecured credit facility with its Chairman and largest shareholder, Richard E. Uihlein, to support its MASH cirrhosis program. The credit line, available until April 2026, carries an interest rate of 6.05% and includes convertible notes and stock purchase warrants. Uihlein highlighted his confidence in the Company's potential, while CEO Joel Lewis emphasized reduced shareholder dilution and...
07-09 12:00
【华鑫宏观策略】七月策略和十大金股
（转自：华鑫研究） ▌ 总量观点 海外关税暂缓周期结束，贸易风波或重启，但中美贸易冲突风险可控。同时中东停火后，全球风险偏好修复；联储降息预期升温...
07-01 09:00
Galectin, Comstock, Cooper, Nutrien, Monday: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($GALT) ), ( ($CRK) ), ( ($COO) ), ...
06-21 17:01
美股牛股 | Circle续涨近34%！上市10天股价累涨逾500%；GHLD升逾25%
美国参议院通过稳定币法案，Circle续涨近34%，上市10天股价累涨逾500%；GHLD升逾25%，公司同意以13亿港元进行私有化交易>>
06-19 16:27
美股牛股 | VERV暴涨逾81%！获礼来13亿收购；APPS绩后涨近57%
VERV暴涨逾81%！获礼来13亿美元溢价130%收购；APPS涨近57%，公司财报表现超预期>>
06-18 18:22
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6
HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces Price Target of $6.
06-17 19:26
Galectin Therapeutics Highlights Belapectin’s Potential in Liver Disease
The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On June ...
06-17 00:28
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics will host a virtual KOL event on June 16, 2025, to discuss unmet needs and treatment options for MASH cirrhosis and portal hypertension. The event will feature experts Naga P. Chalasani, MD, and Naim Alkhouri, MD, FAASLD, DABOM, and highlight results from the company's NAVIGATE Phase 3 trial evaluating belapectin, a galectin-3 targeting drug. B elapectin may address an unmet need for treating varices in MASH cirrhosis. A Q&A...
06-10 12:56
